Efficacy and tolerability of 4-hydroxyandrostenedione (4-OHA) as first-line treatment in postmenopausal patients with breast cancer after adjuvant therapy
- 30 April 1993
- journal article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 19, 31-36
- https://doi.org/10.1016/0305-7372(93)90005-c
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- 4-hydroxyandrostenedione: A new treatment for postmenopausal patients with breast cancerEuropean Journal Of Cancer, 1992
- Towards a molecular basis for tamoxifen resistance in breast cancerAnnals of Oncology, 1992
- Low-dose aminoglutethimide with and without hydrocortisone replacement as a first-line endocrine treatment in advanced breast cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research.Journal of Clinical Oncology, 1992
- Aminoglutethimide in patients with metastatic breast cancerCancer, 1990
- Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study.Journal of Clinical Oncology, 1990
- Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedioneCancer Chemotherapy and Pharmacology, 1990
- Results of salvage hormonal therapy and salvage chemotherapy in women failing adjuvant chemotherapy after mastectomy for breast cancerBreast Cancer Research and Treatment, 1989
- Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancerBreast Cancer Research and Treatment, 1985
- Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial.BMJ, 1981
- Assessment of response to therapy in advanced breast cancerBritish Journal of Cancer, 1977